

---

**Program Memorandum**  
**Carriers**

**Department of Health and  
Human Services (DHHS)  
HEALTH CARE FINANCING  
ADMINISTRATION (HCFA)**

---

**Transmittal B-00-35**

**Date: JULY 20, 2000**

---

**CHANGE REQUEST 1228**

**SUBJECT:** Addition of Five "WW" Codes to Identify a New Source for Methotrexate

Suppliers are currently instructed to bill oral anti-cancer drugs to the DMERCs using the appropriate National Drug Code (NDC) number. The addition of these "WW" codes will allow the DMERCs to adjudicate this oral anti-cancer drug. The proposed additions would read:

WW040 - Methotrexate, 2.5mg, oral (00005-4507-04)  
WW041 - Methotrexate, 2.5mg, oral (00005-4507-05)  
WW042 - Methotrexate, 2.5mg, oral (00005-4507-07)  
WW043 - Methotrexate, 2.5mg, oral (00005-4507-09)  
WW046 - Methotrexate, 2.5mg, oral (00005-4507-91)

Rheumatrex is the brand name for the generic methotrexate.

(DMEPOS category:9)(CWF category:17,60)(POS: 12,31,32,33,54,55,56)(TOS:9)

\*\* NOTE: The "WW" codes are used for DMERC internal systems only. Providers should still bill using the appropriate NDC codes for oral anti-cancer drugs.

**The *effective date* for this Program Memorandum (PM) is October 1, 2000.**

**The *implementation date* for this PM is October 1, 2000.**

**These instructions should be implemented within your current operating budget.**

**This PM may be discarded after October 1, 2001.**

**If you have any questions contact Angie Costello at 410-786-1554 or (acostello@hcfa.gov).**